Absence of potential gadolinium toxicity symptoms following 22,897 gadoteric acid (Dotarem®) examinations, including 3,209 performed on renally insufficient individuals
Sign Up to like & getrecommendations! Published in 2018 at "European Radiology"
DOI: 10.1007/s00330-018-5737-z
Abstract: ObjectivesRecent safety concerns regarding gadolinium-based contrast agents (GdCAs) concluded with the suspension of some agents from the European market, yet a clinical consequence remains unknown. We used electronic health records to investigate the incidence of… read more here.
Keywords: contrast; gadoteric acid; gadolinium toxicity; gadolinium ... See more keywords